Disease severity affects the long-term visual outcome of Peter's anomaly.
Arctic Vision partners with Santen Pharmaceutical Co., Ltd. to commercialise ARVN001 in China
ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications
Higher Molar Dose and Its Translation into Clinical Practice
European Commission approves aflibercept biosimilar OPUVIZ (previously SB15) from Samsung Bioepis
OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases
CHMP issues positive opinion for marketing authorisation of aflibercept biosimilar FYB203 (Formycon)
The positive opinion marks a key regulatory step towards the approval of FYB203, which will go by the trade names AHZANTIVE and Baiama in the European Union
US FDA issues Complete Response Letter for avacincaptad pegol (Izervay, Astellas Pharma Inc)
The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration
NHS introduces OCT programme to reduce annual hospital visits for patients with diabetes
Optical coherence tomography will be in all eye care services by October 2025
